OH-ENOSIX
enosix, Inc., the leading technology provider of real-time, prebuilt SAP data integration solutions, announced the successful completion of its $10 million growth financing led by MK Capital. enosix will use the proceeds to accelerate the development and expansion of its SAP integration platform, while expanding its support of Salesforce, MuleSoft, and ServiceNow clients.
enosix is the proven, SAP data integration approach that is relied upon by leading global manufacturers including recent customer additions, Prevost, a member of Volvo Group, Tremco Inc., and Carl Zeiss AG. enosix empowers SAP ERP customers with the critical last mile of integration in real-time, boosting digital transformation efforts by eliminating error-prone, latent, swivel-chair data entry between systems. enosix uplevels data accuracy, automation and business agility in areas such as, but not limited to, sales quoting, IT asset management, business supply-chain management, B2B eCommerce, and more, allowing for greater utilization of business and SAP skilled resources. These advantages translate to a superior customer experience and greater revenue growth.
“Over the past 30 years we have performed detailed due diligence on hundreds of technology companies,” noted Mark Koulogeorge of MK Capital.“ We have never had a company score higher on product quality and reliability than enosix. The product’s high performance over millions of transactions differentiates enosix from its competitors.”
Jamie Bedard, CEO of SAPinsider observed,“The enterprise landscape for SAP customers continues to become more complex. The accelerated adoption of cloud-based solutions as a result of the global pandemic has only added to this complexity. enosix’s unique approach to real-time, virtualized SAP integration triggers a huge sigh of relief by the SAP industry and offers a potential safety net for tens of thousands of enterprise SAP ERP customers who are not only behind in their S/4HANA migration projects, but those who are trying to keep up with the business demands of digital transformation but don’t have the time, resources, or skilled SAP talent available to support a major traditional integration project.”
Nick Fera, CEO of enosix noted “The increasing demand for pre-built, real-time, bi-directional access to legacy ERP solutions, especially during these difficult economic times, positions enosix for tremendous growth. Companies are tired of paying millions to systems integrators for bespoke integration solutions that offer only synchronous experience and require long-term maintenance. The ability to ‘have a two-way conversation’ with your legacy ERP solutions is no longer a dream, enosix has delivered a platform to handle complex pricing and quoting and is now better positioned to expand.”
About enosix, Inc
enosix is the standard for real-time, prebuilt SAP ERP integration. enosix provides real-time data virtualization, which enables a more agile and compliant customer experience by reducing error-prone data entry and information delays. enosix seamlessly connects SAP ECC and S/4HANA systems to modern front-end systems such as Saleforce, MuleSoft, ServiceNow to support rapid digital transformation. The enosix platform leverages low or no-code Packaged Integration Processes (PIP) so companies can quickly realize value—in weeks instead of months. enosix' use of data virtualization unlocks data, business processes, authorizations, and user permissions from SAP without recreating them from the front-end; delivering the back-end translation in an easy-to-understand, real-time, and bi-directional integration. For more information, visit www.enosix.com
About MK Capital
MK Capital is an early-stage lead investor in the software and cloud services industries. The firm's partners, who average more than 20 years of venture capital experience, actively partner with entrepreneurial management teams to build leading companies that accelerate the digital transformation of the global economy. MK Capital manages over $400 million in capital and is actively seeking new investment opportunities. For more information, visit www.mkcapital.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom